Human medicines European public assessment report (EPAR): Spedra, avanafil, Date of authorisation: 21/06/2013, Date of refusal: 26/04/2013, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Hexacima, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisation: 17/04/2013, Date of refusal: 22/02/2013, Revision: 36, Status: Authorised

Human medicines European public assessment report (EPAR): Hexyon, diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed), Date of authorisation: 17/04/2013, Date of refusal: 22/02/2013, Revision: 37, Status: Authorised

CHMP opinions on consultation procedures on ancillary substances incorporated in a medical device

Clinical Trials Information System (CTIS) bitesize talk: Annual safety report (ASR) new safety module, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 23 July 2026, 13:00 (CEST) to 23 July 2026, 14:30 (CEST)

Surgiflo haemostatic matrix kit - Ferrosan - Procedural steps and scientific information after initial consultation

Guidance for industry on implementing Shortage Prevention Plans (SPP)

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Hyftor, sirolimus, Date of authorisation: 15/05/2023, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Tenkasi (previously Orbactiv), oritavancin, Date of authorisation: 19/03/2015, Revision: 17, Status: Authorised